Clinical Report: Human-Relevant Discovery: iPSC Models and the Future of Rare Disease R&D

Overview

Revise to better reflect the transformative role of iPSC models in drug development.

Background

Rare diseases affect over 300 million individuals globally and pose significant research challenges due to their complexity and the limited availability of patient samples. Traditional drug screening methods often fail to capture the nuances of human biology, which can lead to ineffective therapies. iPSC models offer a promising solution by preserving patient-specific genetics and enabling the study of disease mechanisms in relevant cell types.

Data Highlights

No numerical data provided in the source material.

Key Findings

• iPSC-derived models facilitate earlier drug discovery by aligning research with human biology.
• These models are particularly valuable for complex diseases where traditional models may not be effective.
• Standardized platforms enhance the consistency and reliability of iPSC-derived data.
• Model selection should be driven by the specific biological question rather than a one-size-fits-all approach.
• Regulatory frameworks are evolving to support the integration of iPSC models in rare disease research.

Clinical Implications

Stress the need for flexibility in model selection and the complementary role of iPSCs.

Conclusion

iPSC models represent a significant advancement in the research and development of therapies for rare diseases, offering a more human-relevant approach to understanding disease mechanisms and validating therapeutic targets.

References

1. iXCells Biotechnologies, Source, 2023 -- Human-Relevant Discovery: iPSC Models and the Future of Rare Disease R&D
2. npj Digital Medicine — Advancing the frontier of rare disease modeling: a critical appraisal of in silico technologies
3. Brain — Exploring the Pathophysiology of Neurodevelopmental Disorders Through Brain Organoid Models
4. the medicine maker — The Role of AI in Rare Disease Drug Discovery
5. the pathologist — Digital Twins for Rare Diseases
6. Advancing the frontier of rare disease modeling: a critical appraisal of in silico technologies
7. Exploring the Pathophysiology of Neurodevelopmental Disorders Through Brain Organoid Models
8. The Role of AI in Rare Disease Drug Discovery
9. Digital Twins for Rare Diseases
10. Guidance Document on Good In Vitro Method Practices (GIVIMP), Second Edition
11. FDA Advances Rare Disease Drug Development with New Evidence Principles | FDA
12. https://www.hitcf.org/wp-content/uploads/2025/01/PR-CHOICES-enrolment-complete_final.pdf